Transverse Myelitis Clinical Trial
Official title:
Injured Spinal Cord Pressure Evaluation Study - Transverse Myelitis
ISCoPE-TM will use intra spinal monitoring techniques to assess cord perfusion and metabolism in patients with severe spinal cord damage from transverse myelitis
Transverse myelitis (TM) is a rare inflammatory condition of the spinal cord. It is characterised by rapid onset of motor, sensory or autonomic dysfunction causing neurological deficit. It has a diverse range of causes; most commonly it is associated with multiple sclerosis and neuromyelitis optica also known as Devic's disease or Devic's syndrome, is a heterogeneous condition consisting of the simultaneous inflammation and demyelination of the optic nerve (optic neuritis) and the spinal cord (myelitis). It affects approximately 1900 adults and children in the UK annually, with 350 cases per year of unknown cause. Outcome in TM is variable; e.g. neuromyelitis optica mortality can be 30% . There is a relationship between the severity of neurological symptoms at presentation and the eventual outcome. When a patient is ASIA (American spinal injuries association) A or tetraplegic at presentation, they are less likely to recover than when ASIA B/C or paraplegic. Approximately 30% of patients will be ASIA A-C after a TM episode. There are several pathological mechanisms which could increase the risk of decreased blood supply and further neurological deficit in TM. The ISCoPE study has shown that in traumatic spinal cord injury when swelling causes mechanical compression of the cord against the dura there is increased intra spinal pressure (ISP). The Investigators propose to monitor the ISP and spinal cord metabolites in 10 TM patients with MRI evidence of a swollen enlarged spinal cord. There has never been a study looking at ISP in TM patients before. The optimum blood pressure in patients with TM is not known. The investigators aim to observe a previously unrecognised pathological mechanism of injury in TM. In the future this could lead on to novel treatments to improve drug delivery and neurological outcome in a condition otherwise associated with a poor outcome. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03887273 -
Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis
|
Phase 1/Phase 2 | |
Recruiting |
NCT04721717 -
AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis
|
||
Recruiting |
NCT05630313 -
Gene Sequencing as a Strategy for Identifying Genetic Factors Associated With Serious Adverse Events After Covid-19 Vaccines in Use in Brazil
|
||
Completed |
NCT03942952 -
PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.
|
||
Recruiting |
NCT06147258 -
The Impact of Expressive Emotional Writing on Facilitating Grief Resolution in Adults With Spinal Cord Injury
|
N/A | |
Active, not recruiting |
NCT00445367 -
Biobank For MS And Other Demyelinating Diseases
|
||
Recruiting |
NCT01623076 -
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
|
||
Terminated |
NCT01446575 -
Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis
|
Phase 4 | |
Active, not recruiting |
NCT04564495 -
Home Based Tele-exercise for People With Chronic Neurological Impairments
|
N/A | |
Enrolling by invitation |
NCT00704626 -
Serum Auto-Antibodies in Neurological Diseases
|
||
Completed |
NCT02341950 -
Clinical Trial of a Serious Game for Individuals With SCI/D
|
N/A | |
Completed |
NCT02166346 -
Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)
|
Phase 2 | |
Completed |
NCT00179478 -
Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis
|
Phase 4 | |
Recruiting |
NCT05249595 -
Ultrasound Imaging Based Sensing of Human Ankle Motion Intent and Control Strategies for Ankle Assistance
|
N/A | |
Not yet recruiting |
NCT06055998 -
Frequency ,Etiology and Prognostic Factors of Acute Transverse Myelitis
|
||
Enrolling by invitation |
NCT06163508 -
A Long Term Follow-Up Study for Subjects Who Have Received Q-Cells
|
||
Completed |
NCT03138421 -
Central Pain Study for ABX-1431
|
Phase 1 | |
Recruiting |
NCT05017142 -
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
|